Chiome Bioscience (4583) Reports Earnings: Revenue Up 8.7% YoY

Chiome Bioscience (4583) has released its financial results, reporting revenue up 8.7% YoY to 273 million yen. On the profit front, the company posted an operating loss of 479 million yen, ordinary loss of 481 million yen, and a net loss of 483 million yen. Basic earnings per share (EPS) stood at -6.62 yen.

From a financial and valuation perspective, the equity ratio is 81.9%, with interest-bearing debt at 70 million yen and retained earnings as of June 30, 2026 at approximately -2.487 billion yen. a reference calculation of operating profit or loss plus depreciation and amortization for January–June 2026 was approximately -475 million yen, with a Return on Equity (ROE) of -65.13% and a Return on Assets (ROA) of -46.84%. As a drug discovery biotech firm, monitoring future research and development milestones, monetization progress, and financial dynamics remains essential.

---

Correction (September 19, 2026)：The affected figures and reporting-period labels were corrected after checking the source disclosure. Source disclosure